lecture louis bont_world vaccine conference washington_2015
TRANSCRIPT
![Page 1: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/1.jpg)
Gaps in knowledge of RSV
Louis Bont
![Page 2: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/2.jpg)
ReSViNET: a Clinical RSV Research Network
• A global network of experts in RSV infections and clinical trial infrastructure
• Vision: combine expertise and leadership to decrease the global burden of RSV infection.
• Mission: perform high quality research to improve knowledge of RSV epidemiology, and to develop safe and effective therapeutic and preventive interventions.
1st ANNUAL RSV EXPERT MEETING JANUARY 2015
ORGANISED BY ReSViNET
2014
2015
![Page 3: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/3.jpg)
Outline
1. Morbidity and Mortality
2. Timing of Vaccination
3. RSV, Wheeze and Asthma
![Page 4: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/4.jpg)
RSV Epidemiology
• 34,000,000 Patients • 3,400,000 Hospitalizations • 253,000 Deaths
![Page 5: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/5.jpg)
Pipeline RSV: Vaccines Overview
![Page 6: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/6.jpg)
Can we prevent RSV mortality?
Schickli J Clin Invest 2015
McLellan, Science 2013
Corti Nature 2013
![Page 8: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/8.jpg)
Prevention ICU admisions
• Multicenter ICU study (n=250)
• Healthy term
• Co- morbidity
• Prematurity
• Protection (hypothetical)
• 30 / 60 / 90 / 120 days
• Proportion prevented (%) 0
102030405060708090
100
30 60 90 120P
reve
nta
ble
Pts
(%
)
Duration of Protection (days)
Co-morbidity
0102030405060708090
100
30 60 90 120
Pre
ven
tab
le P
ts (
%)
Duration of Protection (days)
Healthy Term
Scheltema, in progress
![Page 9: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/9.jpg)
Three Distinct Wheezing Phenotypes
RSV Infants wheeze Asthma
Stein Lancet 1999
Sigurs Thorax 2010
Bacharier JACI 2013
![Page 10: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/10.jpg)
RSV and Asthma
RSV Bronchiolitis in Early Life (RBEL), n=206, < 13 months
Asthma < 7y 48%
Active asthma 35%
Bacharier, JACI 2013
![Page 11: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/11.jpg)
Key Facts on Asthma
Unmet Need
Opportunity Risk
One of the major non-communicable diseases 235 million people currently suffer from asthma Common disease among children. Most asthma-related deaths occur in LMIC
Disability adjusted life years
![Page 12: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/12.jpg)
Key Facts on Asthma
Unmet Need
Opportunity Risk
Costs in the United States “The annual direct health care cost of asthma is approximately $50.1 billion; indirect costs
(e.g. lost productivity) add another $5.9 billion, for a total of $56 billion dollars”
![Page 13: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/13.jpg)
Prevention of Asthma
Unmet Need
Opportunity Risk
Prevention of Asthma Tobacco Smoke Exposure Respiratory Tract Infection Pollution
![Page 14: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/14.jpg)
Chicken or Egg
Blanken NEJM 2013
Serial hypothesis Parallel hypothesis
Pre-existent healthy
Viral bronchiolitis
Recurrent wheeze
Pre-existent susceptibility
Viral
bronchiolitis
Recurrent
wheeze x
x
![Page 15: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/15.jpg)
RSV and Wheeze
0
500
1000
1500
2000
2500
1 2 3 4 5 6 7 8 9 10 11 12
Cum
ula
tive w
heezin
g d
ays
Month follow-up
PalivizumabPlacebo
p<0.0001
Blanken NEJM 2013
![Page 16: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/16.jpg)
Studying Long-term effects
1. Clinical Relevance (Quality of Life)
2. Societal Relevance (56 billion$)
3. Mechanism of Disease (parallel vs serial hypothesis)
4. Feasibility (small sample size)
![Page 17: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/17.jpg)
Conclusions
1. Morbidity and Mortality
2. Timing of Vaccination
3. RSV, Asthma and Wheeze 0
500
1000
1500
2000
2500
1 2 3 4 5 6 7 8 9 10 11 12
Cu
mu
lative w
he
ezin
g d
ays
Month follow-up
PalivizumabPlacebo
![Page 18: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/18.jpg)
Save The Date To Meet RSV Experts
DATE 19-21 JANUARY 2016 LOCATION THE NETHERLANDS WEBSITE www.resvinet.org
![Page 19: Lecture Louis Bont_World Vaccine Conference Washington_2015](https://reader035.vdocument.in/reader035/viewer/2022062420/55c16072bb61eb9e508b4609/html5/thumbnails/19.jpg)
CONTACT ReSViNET Louis Bont (ReSViNET Chairman ) [email protected] +31 (0) 88 75 75 114
Leyla Kragten-Tabatabaie (Network Manager)
[email protected] +31 (0) 611 33 13 91
Cyrus Park (Manager Clinical Research & Development)
[email protected] +31 (0) 621 16 29 69